Insider buying last 90 days
No open-market insider purchases were filed for TNDM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TNDM insider filing, plotted on the chart in Gekko.Open TNDM in Gekko
NASDAQ: TNDM
Tandem Diabetes Care (TNDM) Stock Analysis & Forecast
Oct 12 close
$16.45+0.34 (+2.1%)
Gekko Brief
AI summaryOct 12 closeTandem Diabetes Care reported Q2 2026 results this week, with worldwide pump shipments up over 10% year-over-year, gross margin improvement, and a 6% increase tied to its pay-as-you-go pharmacy model and the global launch of Control-IQ and Mobi; quarterly revenue came in at $254.56 million with a GAAP net loss of $21.17 million. Alongside this, Tandem issued a Class II recall for its iOS t:slim mobile app version 2.13 after a pairing issue disrupted automated insulin delivery for 177 beta users. Barclays downgraded the stock from Overweight to Hold, cutting its price target from $50 to $18, and has since reiterated that Hold rating with the $18 target.
TNDM closed at $16.45, up 2.1%, sitting between its 50-day average of $19.28 and 200-day average of $19.25. The GekkoIndex reads 63.3, placing the stock in the Accumulation zone, though the reading has slipped 1.8 over five days. Price sits 27.3% below Gekko Fair Value of $22.62.
The next earnings date falls on 5 November 2026, after the close, within the next 20 trading days. Across the last eight quarters, Tandem beat estimates in four, with an average absolute reaction of 18.2% and a -14.1% reaction to the last report. Seasonality from this point in the calendar has averaged -6% over the next 20 trading days across 5 years, rising in 2 of them. Consensus among 15 firms stands at 8 buy and 7 hold ratings, with a consensus target of $27.86.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Tandem Diabetes Care price vs fair value
Close $16.45200-day averageGekko Fair Value $22.62
Tandem Diabetes Care quick facts
- Market cap
- $1.13B
- P/E ratio
- —
- Forward P/E
- 117.7
- EPS, TTM
- −$0.91
- Revenue, TTM
- $1.04B
- Profit margin
- -6.1%
- Dividend yield
- —
- Beta
- 1.66
- Volume
- 1.58M avg 2.33M
- 1-year return
- +11.0%
- Typical daily move
- ±6.1%
- Typical 20-day move
- ±12.6%
- 50-day average
- $19.28
- 200-day average
- $19.25
- Next earnings
- Nov 5 after close
- Shares outstanding
- 69.58M
Tandem Diabetes Care swing-trade checklist
Tandem Diabetes Care scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $16.45 sits between the 50-day ($19.28) and 200-day ($19.25) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
63.3, Accumulation
Reading 63.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
27.3% below
Price is 27.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.0% on average
From this point in the calendar, the next 20 trading days averaged −6% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Tandem Diabetes Care stock chart and price history
Tandem Diabetes Care closed at $16.45 on Oct 12, 2026, +11.0% over the past year, inside a 52-week range of $12.26 to $29.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.9%
- 3 months
- +5.9%
- 6 months
- −18.2%
- 1 year
- +11.0%
The full TNDM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TNDM in Gekko
Follow Tandem Diabetes Care through every session
Put TNDM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TNDM in GekkoFree for 7 days. No credit card required.
About Tandem Diabetes Care
Tandem Diabetes Care builds and sells devices for people worldwide who depend on insulin to manage diabetes. Its main product is the t:slim X2 insulin delivery system, a pump platform made up of the pump itself, a 300-unit disposable insulin cartridge, and an infusion set. The system can run added features such as Basal-IQ and Control-IQ technology and G5 Integration, giving users more automated ways to track and adjust their insulin delivery.
Beyond the pump, the company supports users with software tools: the Tandem Device Updater lets patients update their pump remotely, while t:connect gathers data from the pump, continuous glucose monitors, and compatible blood glucose meters into one web-based view for patients, caregivers, and clinicians. It also offers the Sugarmate app for insulin users. Tandem works with Dexcom and Abbott Laboratories on developing and bringing its technology to market.
The company was founded in 2006 under the name Phluid Inc. and took the Tandem Diabetes Care name in January 2008. It is headquartered in San Diego, California, and its shares are listed on the NASDAQ under the ticker TNDM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- tandemdiabetes.com
Tandem Diabetes Care GekkoIndex: the smart money zone
Tandem Diabetes Care’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.3, in the Accumulation zone, down 1.8 points over five sessions.
63.3Accumulation
Down 1.8 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 91 | −0.3% | +0.2% | ||
| Accumulation (current zone) | 230 | +0.7% | +2.4% | ||
| Neutral | 324 | −0.2% | +0.4% | ||
| Distribution | 35 | +2.9% | +1.9% | ||
| Selling | 2 | Too few readings yet | |||
Average TNDM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the TNDM price, zone by zone.Track TNDM in Gekko
Is Tandem Diabetes Care stock overvalued? Gekko Fair Value
Tandem Diabetes Care trades 27.3% below Gekko Fair Value of $22.62, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Tandem Diabetes Care shares are worth, recalculated every trading day.
$22.62
Gekko Fair Value, Oct 10, 2026
27.3% Undervalued
At the end of Aug 2026 the price was 12.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TNDM in Gekko
Tandem Diabetes Care insider and Congress trading
No open-market insider purchases were filed for Tandem Diabetes Care, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TNDM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TNDM, plotted on the chart in Gekko.Open TNDM in Gekko
Buybacks
Tandem Diabetes Care has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2024
- $3.00M
- As a share of market cap
- 0.27%
From company filings.
Tandem Diabetes Care earnings: next date and track record
Tandem Diabetes Care reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- −$0.25
- Revenue estimate
- $265.9M
4 of 8reports beat the EPS estimate
±18.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 7, 2026 AI summary
- What they said
- Tandem Diabetes Care reported strong Q1 2026 financial and operational performance. Key initiatives include direct commercial launches in UK, Switzerland, and Austria, and a U.S. multichannel PayGo pharmacy strategy with ~40% formulary coverage. Tandem Mobi expanded to Android smartphones, and Control-IQ+ received FDA clearance for use in pregnant women with type 1 diabetes. The company is investing in sales infrastructure and transitioning business models for improved margins.
- Guidance
- Management expects continued expansion of direct international operations in 2026 and 2027. PayGo pharmacy transition is progressing, with formulary coverage at 40% as an early leading indicator. Additional new product offerings are on track for Q2 2026 delivery.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 7, 2026 | −$0.30 est −$0.41 | $247.2M est $240.4M | −14.1% |
| Feb 19, 2026 | −$0.01 est −$0.05 | $290.4M est $277.0M | +29.7% |
| Nov 6, 2025 | −$0.31 est −$0.31 | $249.3M est $276.9M | +10.8% |
| Aug 6, 2025 | −$0.48 est −$0.40 | $240.7M est $250.2M | −24.0% |
| Apr 30, 2025 | −$0.67 est −$0.60 | $234.4M est $220.2M | +19.1% |
| Feb 26, 2025 | −$0.44 est −$0.24 | $282.6M est $251.4M | −34.8% |
| Nov 6, 2024 | −$0.35 est −$0.40 | $363.3M est $251.5M | +0.6% |
| Aug 1, 2024 | −$0.48 est −$0.54 | $221.9M est $204.9M | +12.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Tandem Diabetes Care stock forecast and analyst price targets
Analysts’ average 12-month price target for Tandem Diabetes Care is $27.86, +69.4% from the last close, from 15 firms rating the stock in the last 90 days.
$27.86consensus 12-month target, +69.4% from the last close
Now $16.45Avg $27.86
Low $16High $50
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Barclays | $18 | +9.4% |
| Sep 30 | Citi | $20 | +21.6% |
| Sep 28 | Lake Street | $50 | +204.0% |
| Sep 24 | Truist Financial | $28 | +70.2% |
| Aug 21 | William Blair | — | — |
+2.4%average 20-day move after past Accumulation readings
−6.0%average move over the next 20 trading days in the last 5 years
±6.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Tandem Diabetes Care seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Tandem Diabetes Care averaged −6.0% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 2 of 5 |
| Next 10 trading days | −0.5% | 3 of 5 |
| Next 15 trading days | −1.9% | 2 of 5 |
| Next 20 trading days | −6.0% | 2 of 5 |
| Next 30 trading days | +0.9% | 2 of 5 |
For scale, TNDM’s typical 20-trading-day move in either direction is about 12.6%.
Tandem Diabetes Care market cap and key statistics
Tandem Diabetes Care’s market cap is $1.13B and revenue of $1.04B over the last twelve months.
Valuation
- Market cap
- $1.13B
- Forward P/E
- 117.7
- EPS, TTM
- −$0.91
- Gekko Fair Value
- $22.62
Trading
- Volume
- 1.58M
- Avg volume, 20 days
- 2.33M
- 52-week high
- $29.65
- 52-week low
- $12.26
- Shares outstanding
- 69.58M
Financials
- Revenue, TTM
- $1.04B
- Profit margin
- -6.1%
- Return on equity
- -48%
- Quarterly earnings growth, YoY
- −37.0%
Risk and income
- Beta
- 1.66
- Typical daily move
- ±6.1%
- Typical 20-day move
- ±12.6%
Tandem Diabetes Care stock news this week
Coverage of Tandem Diabetes Care this week reads neutral: 3 positive, 6 neutral and 2 negative headlines.
- Tandem Diabetes Care Q2 2026 Earnings Call TranscriptBenzinga, Oct 12
- App Recall Might Change The Case For Investing In Tandem Diabetes Care (TNDM)Simply Wall Street, Oct 11
- Tandem Diabetes Care, Inc. (TNDM) Stock forecastsYahoo Finance Singapore, Oct 11
- Barclays Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $18Moomoo, Oct 10
- Is it the Right Time to Hold TNDM Stock in Your Portfolio?TradingView, Oct 9
- Barclays Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)The Globe and Mail, Oct 9
Tandem Diabetes Care peers
Tandem Diabetes Care’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Tandem Diabetes Care stock FAQ
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.13B at the Oct 12, 2026 close of $16.45, with 69.58M shares outstanding.
What is the Tandem Diabetes Care stock forecast?
The consensus analyst 12-month price target for Tandem Diabetes Care is $27.86, +69.4% from the last close. Of the 15 firms that rated the stock in the last 90 days, 8 rate it a buy, 7 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Tandem Diabetes Care stock overvalued or undervalued?
On Gekko’s estimate Tandem Diabetes Care is undervalued: the Oct 12, 2026 close of $16.45 is 27.3% below Gekko Fair Value of $22.62. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Tandem Diabetes Care report earnings next?
Tandem Diabetes Care is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of −$0.25 per share on revenue of $265.9M. Tandem Diabetes Care beat the earnings estimate in 4 of its last 8 reports, moving 18.2% on average across the report.
What is Tandem Diabetes Care’s 52-week high and low?
Tandem Diabetes Care’s 52-week high is $29.65 and its 52-week low is $12.26; it closed at $16.45 on Oct 12, 2026, +11.0% over the past year. Over the last five years the shares peaked at $155.86 on Dec 28, 2021.
Is Tandem Diabetes Care stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Tandem Diabetes Care the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.